B. cepacia, short for Burkholderia cepacia, is a group of closely related bacteria found naturally in soil and water that can cause serious lung infections in people with cystic fibrosis or weakened immune systems. The full name for this group is the Burkholderia cepacia complex (BCC), and it includes at least 22 distinct bacterial species. For most healthy people, these bacteria are harmless. For vulnerable populations, they can be life-threatening.
Where B. Cepacia Lives
B. cepacia bacteria are remarkably versatile. They thrive in soil, rivers, lakes, seawater, and even drinking water. They colonize the root zones of plants, where they actually do useful work: fighting plant pests, promoting growth, and breaking down toxic chemicals. One study in Bologna, Italy, found B. cepacia in 3.5% of drinking water samples collected from public and private buildings, growing at roughly 24°C (about 75°F). The bacteria can feed on the thin layer of organic material that naturally forms inside water pipes.
This ability to survive on almost nothing makes B. cepacia a persistent problem in hospitals and manufacturing facilities. The bacteria can grow in water-based products that contain only trace amounts of nutrients. They’ve been found in contaminated antiseptic soaps, skin cleansers, foam hand washes, and other products that are supposed to be sterile. In 2023, DermaRite Industries recalled multiple product lines, including antimicrobial soaps and antiseptic cleansers, after B. cepacia contamination was identified. The FDA noted that contaminated products posed the greatest risk to immunosuppressed individuals, in whom the bacteria could enter the bloodstream and cause life-threatening sepsis.
Researchers have also found B. cepacia species in the soil and water around the homes of cystic fibrosis patients, suggesting the home environment itself can be a reservoir for infection.
Why It’s Dangerous for Certain People
B. cepacia is primarily a threat to two groups: people with cystic fibrosis (CF) and people with chronic granulomatous disease, a rare inherited immune disorder. Immunocompromised individuals, such as those undergoing chemotherapy or organ transplant recipients, are also at elevated risk.
In people with CF, B. cepacia can establish chronic lung infections that accelerate lung damage far beyond the typical course of the disease. Unlike many opportunistic bacteria, B. cepacia doesn’t tend to live harmlessly on the body first. Infections are typically picked up either in a hospital or directly from the environment. One Italian CF center reported that 23% of its patients were colonized with B. cepacia complex bacteria over the study period, with 90% of those infections caused by a single species, B. cenocepacia.
For healthy people, B. cepacia poses minimal risk. Even with minor skin wounds, exposure typically leads to nothing more than a localized infection, if anything at all.
Cepacia Syndrome
The most feared complication of B. cepacia infection in CF patients is called cepacia syndrome. This is a sudden, severe pneumonia characterized by high fever, bacteria flooding the bloodstream, and rapidly worsening respiratory failure. It’s rare, but it kills about half the people who develop it.
Cepacia syndrome doesn’t happen right after someone first picks up the bacteria. A systematic review of cases reported over the past two decades found the median time between initial B. cepacia infection and the onset of cepacia syndrome was five years, with a range of one to 26 years. The median age at onset was 22, though cases have been reported in patients as young as 10 and as old as 60. B. cenocepacia is the species most commonly responsible.
The severity of B. cenocepacia infection in particular has led many transplant centers to consider it a disqualifying factor for lung transplantation, making it one of the few bacterial infections that can directly close off a major treatment option for CF patients.
Why B. Cepacia Is So Hard to Treat
B. cepacia is naturally resistant to a wide range of antibiotics, which is a major reason it’s so feared in clinical settings. This resistance isn’t something the bacteria need to acquire from other germs. It’s built into their biology through several overlapping defense mechanisms.
The bacteria produce enzymes that break down common antibiotics before they can work. They have molecular pumps embedded in their cell walls that actively push antibiotics back out of the cell. At least six of these pump systems have been identified in B. cenocepacia alone. The outer membrane of the bacteria also acts as a physical barrier, with reduced entry points that make it harder for drugs to get inside. On top of all that, the bacteria can alter the specific cellular targets that antibiotics are designed to attack, rendering those drugs ineffective even if they do get through.
B. cepacia is also resistant to certain common hospital disinfectants at lower concentrations. Research has shown that some strains can survive in chlorhexidine (a widely used antiseptic) at concentrations as high as 500 micrograms per milliliter. Since some commercial products contain chlorhexidine at concentrations as low as 200 micrograms per milliliter, these products may not reliably kill the hardiest strains. This helps explain why contaminated products sometimes make it to market and why hospital outbreaks can be difficult to stamp out.
How CF Centers Manage the Risk
Because B. cepacia spreads so readily and is so difficult to eradicate once it establishes a lung infection, CF care centers have adopted strict segregation policies. Patients colonized with B. cepacia are kept separate from uncolonized patients during clinic visits and hospital stays. This approach has meaningfully reduced the rate of new infections over time.
Treatment for established infections remains a significant challenge. No clear, reliable antibiotic regimen exists for clearing B. cepacia from the lungs, and therapies that work for other CF-related bacteria often fail against it. Clinicians typically rely on combinations of antibiotics guided by laboratory testing of each patient’s specific bacterial strain, but outcomes are inconsistent. The combination of innate drug resistance, limited treatment options, and the potential for cepacia syndrome is what makes B. cepacia one of the most serious bacterial threats in cystic fibrosis care.